Boehringer buckles in AbbVie patent fight, saving Humira from biosims until 2023
admin 14th May 2019 Uncategorised 0Boehringer Ingelheim fought hard against AbbVie’s so-called “patent thicket” surrounding the world’s bestselling med, Humira. But in the end, the German company ended up settling on a 2023 launch date, just like its fellow biosimilar makers.
More: Boehringer buckles in AbbVie patent fight, saving Humira from biosims until 2023
Source: fierce